Adaptive Biotechnologies Corp
ADPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.81B
Close$
$3.64
79% downside
Current Fair Value
79% downsideOvervalued by 79% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.81 Billion |
|---|---|
| Enterprise Value | $2.99 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 2.15 |
| Outstanding Shares | 155,521,048 |
Return
| Return on Equity | -22.96% |
|---|---|
| Return on Assets | -9.82% |
| Return on Invested Capital | -10.35% |
Valuation & Multiples
| P/E Ratio | -53.54 |
|---|---|
| PEG | 162.78 |
| Price to Sales | 17.37 |
| Price to Book Ratio | 17.37 |
| Enterprise Value to Revenue | 10.11 |
| Enterprise Value to EBIT | -68.88 |
| Enterprise Value to Net Income | -61 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 1.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$61.03 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.81 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1511▼ 43.27% |
|---|---|
| Total Calls | 76,100▼ 9.51% |
| Total Puts | 11,500▼ 76.58% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.17%▲ 1.02% |
|---|---|
| Total Invested | $2.11B▼ 13.65% |
| Investors Holding | 299▲ 12.00% |
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...